Highlights
-
There is a paucity of real-world data on the persistence of drug therapy between warfarin and non vitamin K antagonist oral anticoagulants
-
ORBIT-AF was used to compare the persistence of warfarin vs. dabigatran in a contemporary cohort of AF patients
-
Warfarin persistence was greater than dabigatran at 6 and 12 months, respectively
-
Future studies evaluating persistence of other non vitamin K antagonist oral anticoagulants as well as the implementation of effective strategies to improve persistence are needed
Introduction
Methods
Study population
Data collection and study endpoints
Statistical analysis
Results
Patient characteristics
Persistence of therapy
Characteristics and predictors of warfarin and dabigatran persistence
Risk factor | Dabigatran adjusted HR (95% CI) |
p value | Warfarin adjusted HR (95% CI) |
p value |
---|---|---|---|---|
Duration of AF < 3 years | – | – | 1.15 (1.10–1.22) | <. 0001 |
Prior catheter ablation of AF | – | – | 0.58 (0.45–0.74) | <. 0001 |
Most recent ECG-sinus rhythm | – | – | 0.72 (0.61–0.85) | <. 0001 |
Age, years (per 10 year increase) | – | – | 1.14 (1.06–1.22) | .0002 |
Persistent AF vs. first onset | – | – | 1.91 (1.35–2.69) | .0002 |
Cognitive impairment | – | – | 0.56 (0.40–0.80) | .001 |
Paroxysmal AF vs. first onset | – | – | 1.68 (1.21–2.33) | .002 |
Heart rate > 80 | – | – | 0.94 (0.90–0.98) | .004 |
CHA2DS2VASC high vs. low | 5.69 (1.50–21.55) | .01 | 1.94 (1.18–3.19) | .009 |
25 < BMI ≤ 38 | 1.05 (1.01–1.09) | .02 | – | |
LVH | – | – | 1.40 (1.08–1.81) | .01 |
Permanent AF vs. first onset | – | – | 1.55 (1.08–2.23) | .02 |
African American vs. White | – | –– | 1.53 (1.07–2.19) | .02 |
Hispanic vs. White | – | – | 1.66 (1.06–2.60) | .03 |
CHA2DS2VASC medium vs. low | 3.95 (0.95–16.38) | .06 | 1.12 (0.66–1.92) | .67 |